Abstract
The development of new drugs for treatment of HIV has increased the efficacy and the quality of life together with decreased unwanted side-effect for people living with HIV. The integrase inhibitor dolutegravir has in short time become part of the first-line treatment in many countries, but is not a recommended first-line drug in pregnancy. As there are few publications of dolutegravir use during pregnancy, we found it valuable to analyze the Stockholm pregnancy cohort. A retrospective analysis of all pregnant women and their infants exposed to dolutegravir at Karolinska University Hospital, 2014–August 2017. Information about maternal health, treatment, pregnancy, and child outcome were collected. Thirty-six women with singleton pregnancies were included. Four early spontaneous abortions occurred. One late termination was performed and one was lost to follow-up. Fourteen were on dolutegravir before and 22 started during pregnancy. Eighteen delivered by caesarean section, three of them because of HIV RNA > 50 copies/mL. The preeclampsia rate and the maternal liver function were normal. One infant was delivered in GW 34 on maternal indication and the rest in full term. No gross malformations were noted. All infants received antiretroviral prophylaxis and have tested negative on follow-up. No increased maternal or infant morbidity was detected in this retrospective study of dolutegravir during pregnancy. This is so far one of the largest observational studies of dolutegravir treatment during pregnancy, but the number is indeed small, and further studies are needed to evaluate the safety and efficacy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutierrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kummerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J, Group PS (2016) Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA 316(2):171–181. https://doi.org/10.1001/jama.2016.5148
Naver L, Albert J, Bottiger Y, Carlander C, Flamholc L, Gisslen M, Josephson F, Karlstrom O, Lindborg L, Svedhem-Johansson V, Svennerholm B, Sonnerborg A, Yilmaz A, Pettersson K (2014) Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013. Scand J Infect Dis 46(6):401–411. https://doi.org/10.3109/00365548.2014.898333
Kandel CE, Walmsley SL (2015) Dolutegravir—a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Devel Ther 9:3547–3555. https://doi.org/10.2147/DDDT.S84850
Mounce ML, Pontiggia L, Adams JL (2017) A single-center retrospective cohort analysis of maternal and infant outcomes in HIV-infected mothers treated with integrase inhibitors during pregnancy. Infect Dis Ther. https://doi.org/10.1007/s40121-017-0170-1
Westling K, Pettersson K, Kaldma A, Naver L (2012) Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy. AIDS Patient Care STDs 26(12):714–717. https://doi.org/10.1089/apc.2012.0283
Thorne C, Favarato G, Peters H, Soriano-Arandes T, Floridia M CA, et al. (2017) Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir. Paper presented at the 9th IAS Conference on HIV Science 23–26 July, Paris
Zash R, Jacobson D, Mayondi G DM, Makhema J, Mmalane MEA (2017) Dolutegravir / tenofovir / emtricitabine (DTG/TDF/FTC) started in pregnancy is as safe as efavirenz / tenofovir /emtricitabine (EFV/TDF/FTC) in nationwide birth outcomes surveillance in Botswana. Paper presented at the 9th IAS Conference on HIV Science, Paris
Pain JB, Le MP, Caseris M, Amiel C, Lassel L, Charpentier C, Desnoyer A, Farnoux C, Pialoux G, Descamps D, Peytavin G (2015) Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy. Antimicrob Agents Chemother 59(6):3660–3662. https://doi.org/10.1128/AAC.00173-15
Pinnetti C, Tintoni M, Ammassari A, Tamburrini E, Bernardi S, Liuzzi G, Scambia G, Perno CF, Floridia M, Antinori A, Cavaliere AF (2015) Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1. AIDS 29(18):2534–2537. https://doi.org/10.1097/QAD.0000000000000888
Antiretroviral Pregnancy Registry International Interim Report for Wilmington NRCC (1 January 1989 through 31 January 2017) Committee. APRS. http://www.apregistry.com/
Thorne C, Newell ML (2004) Prevention of mother-to-child transmission of HIV infection. Curr Opin Infect Dis 17(3):247–252
Zash R, Souda S, Chen JY, Binda K, Dryden-Peterson S, Lockman S, Mmalane M, Makhema J, Essex M, Shapiro R (2016) Reassuring birth outcomes with tenofovir/emtricitabine/efavirenz used for prevention of mother-to-child transmission of HIV in Botswana. J Acquir Immune Defic Syndr 71(4):428–436. https://doi.org/10.1097/QAI.0000000000000847
Schalkwijk S, Greupink R, Colbers AP, Wouterse AC, Verweij VG, van Drongelen J, Teulen M, van den Oetelaar D, Burger DM, Russel FG (2016) Placental transfer of the HIV integrase inhibitor dolutegravir in an ex vivo human cotyledon perfusion model. J Antimicrob Chemother 71(2):480–483. https://doi.org/10.1093/jac/dkv358
Christensen ES, Jain R, Roxby AC (2017) Abacavir/dolutegravir/lamivudine (Triumeq)-induced liver toxicity in a human immunodeficiency virus-infected patient. Open Forum Infect Dis 4(3):ofx122. https://doi.org/10.1093/ofid/ofx122
Curtis L, Nichols G, Stainsby C, Lim J, Aylott A, Wynne B, Clark A, Bloch M, Maechler G, Martin-Carpenter L, Raffi F, Min S (2014) Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients. HIV Clin Trials 15(5):199–208. https://doi.org/10.1310/hct1505-199
Guidelines U (2017) Recommendations for use of antiretroviral Drugs in pregnant HIV-1 infected women. https://aidsinfo.nih.gov/guidelines
Zinaman MJ, Clegg ED, Brown CC, O'Connor J, Selevan SG (1996) Estimates of human fertility and pregnancy loss. Fertil Steril 65(3):503–509
Michels TC, Tiu AY (2007) Second trimester pregnancy loss. Am Fam Physician 76(9):1341–1346
Lewis JM, Railton E, Riordan A, Khoo S, Chaponda M (2016) Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing. AIDS 30(8):1313–1315. https://doi.org/10.1097/QAD.0000000000001055
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
L.N. has received payment from Gilead Sciences Sweden for a lecture 2015 and for participating in an advisory board 2015.
K.W. has received speaker fees from companies AbbVie, Bristol Myers Squibb, and Gilead Sciences; has participated on advisory boards for companies AbbVie, Bristol Myers Squibb, and Janssen Cilag; and received research funding for previous research from GSK/ViiV.
R.B., S.S.A., and K.P. have no conflicts of interest.
Ethical approval and informed consent
The study was approved by the Regional Ethical Review Board in Stockholm, Sweden (Dnr: 2015/2218-31/2) with no requirements for informed consent.
No informed consent was received from the included patients due to the study design of retrospective analysis of medical records.
Rights and permissions
About this article
Cite this article
Bornhede, R., Soeria-Atmadja, S., Westling, K. et al. Dolutegravir in pregnancy—effects on HIV-positive women and their infants. Eur J Clin Microbiol Infect Dis 37, 495–500 (2018). https://doi.org/10.1007/s10096-018-3195-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-018-3195-9